What is the treatment for fungal urinary tract infections (UTIs) in female patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Fungal Urinary Tract Infections in Female Patients

Fluconazole is the first-line treatment for symptomatic fungal urinary tract infections in female patients, with a recommended dose of 200-400 mg daily for 2 weeks. 1

Diagnostic Considerations

Before initiating treatment, it's important to distinguish between fungal colonization and true infection:

  • Fungal concentration >10³/mm³ in urine suggests significant funguria 2
  • Presence of symptoms (dysuria, frequency, urgency) indicates need for treatment
  • Obtain urine culture to identify the specific fungal species and guide therapy

Treatment Algorithm

1. Asymptomatic Candiduria

  • No treatment required in most cases 1
  • Remove predisposing factors (indwelling catheters, antibiotics) which will clear candiduria in almost 50% of cases 3
  • Treatment indicated only for high-risk patients:
    • Neutropenic patients
    • Patients undergoing urologic procedures
    • Pregnant women

2. Symptomatic Cystitis

  • First-line treatment: Fluconazole 200-400 mg daily for 2 weeks 1
  • Alternative for fluconazole-resistant species (e.g., C. glabrata, C. krusei):
    • Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days 1
    • Flucytosine 25 mg/kg four times daily for 7-10 days 1

3. Pyelonephritis

  • Fluconazole 200-400 mg daily for 2 weeks 1
  • Alternative therapy for resistant organisms:
    • Amphotericin B deoxycholate 0.5-0.7 mg/kg daily with or without flucytosine 1

4. Fungal Balls (Mycetoma)

  • Surgical removal strongly recommended 1
  • Antifungal therapy should be administered concurrently
  • Local irrigation with amphotericin B may be used as an adjunct to systemic therapy 1

Special Considerations

Resistant Organisms

  • C. glabrata and C. krusei often show resistance to fluconazole
  • For these species, consider:
    • Amphotericin B bladder irrigation
    • Flucytosine (if susceptible)
    • Removal of any obstructing lesions 1

Catheters and Stents

  • Remove or exchange indwelling catheters whenever possible 2
  • For patients with permanent drainage tubes or stents and symptomatic fungal UTIs:
    • Ensure fungicidal levels are present before exchanging tubes/stents 1

Monitoring

  • Follow-up urine cultures to confirm eradication
  • Monitor renal function when using amphotericin B due to nephrotoxicity risk 4

Prevention Strategies

  • Limit antibiotic use to reduce risk of fungal overgrowth 2
  • Optimize diabetes management in diabetic patients 2
  • Prompt removal of urinary catheters when no longer needed 2, 3

Important Caveats

  • Newer azoles and echinocandins are not recommended for urinary tract infections as they fail to achieve adequate urine concentrations 3
  • The ability of the antifungal agent to achieve adequate concentrations in urine is as important as the antifungal susceptibilities of the infecting species 1
  • Fluconazole is particularly effective because it is excreted into the urine in its active form and easily achieves urine levels exceeding the MIC for most Candida isolates 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Management of fungal urinary tract infections].

Presse medicale (Paris, France : 1983), 2007

Research

Candida urinary tract infections: treatment options.

Expert review of anti-infective therapy, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.